Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

Leukaemia breakthrough halts disease progression

  • Comment

Leukaemia could be stopped in its tracks by neutralising rogue blood cells that fuel the disease, a study has revealed.

By suppressing a protein in the blood called beta-catenin, scientists found they could switch leukaemic stem cells back to a pre-cancerous stage of development.

The study also showed that more aggressive leukaemic stem cells that had become resistant to treatment could be “re-sensitised” to anti-cancer drugs.

The groundbreaking study, reported in the journal Cancer Cell, involved a dangerous strain of leukaemia driven by defects in the MLL (mixed lineage leukaemia) gene.

MLL cancer accounts for around 70% of infant leukaemias and 10% of those affecting adults.

Only 50% of children diagnosed with MLL leukaemia survive longer than two years after receiving standard therapy.

Professor Eric So, who led the King’s College London team, said: “These results are extremely exciting and represent a critical step forward in the search for more effective treatments for this devastating form of leukaemia.

“The findings provide compelling evidence that this protein could be exploited to develop an effective therapeutic target for this form of the disease.”

The scientists found suppressing the beta-catenin protein delayed the onset of cancer, slowed down cancer growth, and reversed leukaemic stem cells to a pre-cancerous stage.

Laboratory studies on leukaemic cells from human patients again showed that suppressing beta-catenin lessened their ability to multiply and renew themselves.

  • Comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.